Orphan drug designation granted to Oncophage for glioma

Antigenics Inc. was granted orphan drug designation by the FDA for its drug candidate, Oncophage (vitespen), which is used for the treatment of glioma (brain cancer). Currently, Oncophage is in a Phase 2 recurrent glioma study.

Oncophage is a patient-specific vaccine designed to reprogram the immune system to target only cancer cells bearing an ‘antigenic fingerprint' derived from each individual's tumor cells.  

For more information call (781) 674-4400 or visit www.antigenics.com.